Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

LLM 2021 | Current treatments and new developments for adult ATLL

Adrienne Phillips, MD, Weill Cornell Medicine, New York, NY, discusses current treatments and novel strategies for adult T-cell leukemia/lymphoma (ATLL). In the past few years, there has been a lot of progress in ATLL treatment, which was a hematological malignancy with a dismal prognosis for many years. Dr Phillips explains that allogeneic hematopoietic stem cell transplantation (allo-HSCT) is currently the best treatment strategy for transplant-eligible patients. For relapsed/refractory patients and not transplant-eligible patients, mogamulizumab represents a promising alternative inducing response rates (RR) ranging between 40-50%. In addition, lenalidomide has been approved in Japan for ATLL. Novel strategies including brentuximab vedotin and histone deacetylase (HDACs) inhibitors are also being investigated in ATLL. This interview took place at the Lymphoma, Leukemia & Myeloma Congress 2021.